Newsbenzinga
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study
· Published
Article summary
Context Therapeutics reports 29% ORR in evaluable ovarian cancer patients treated with CTIM-76, with favorable safety data.
An excerpt from the original article.
Comments —
Loading comments…